SBL
AKRO

Sargent Bickham Lagudis’s Akero Therapeutics AKRO Stock Holding History

Sargent Bickham Lagudis’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$9K – 920
2021
Q1 		$9K Hold
300
– – ﹤0.01% 708
2020
Q4 		$8K Hold
300
– – ﹤0.01% 683
2020
Q3 		$9K Buy
+300
New +$10.5K ﹤0.01% 608

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sargent Bickham Lagudis's AKRO Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of Akero Therapeutics (AKRO) in Q2 2021, closing a stake of 300 shares — an estimated $9K sold.

Sargent Bickham Lagudis first reported a position in AKRO in Q3 2020 and held it in 3 quarters. The position peaked at $9K in Q1 2021. 97 funds tracked by Wall St. Rank hold AKRO as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining Akero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 300 Akero Therapeutics shares in Q2 2021, an estimated $9K.
  • Sargent Bickham Lagudis first reported a position in Akero Therapeutics in Q3 2020 and held it in 3 quarters.
  • Sargent Bickham Lagudis's Akero Therapeutics position peaked at $9K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.